For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...

Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...